You are currently viewing a new version of our website. To view the old version click .
Gels
  • This is an early access version, the complete PDF, HTML, and XML versions will be available soon.
  • Article
  • Open Access

20 December 2025

Biocompatibility and Drug Release Properties of Carboxymethyl Cellulose Hydrogel for Carboplatin Delivery

,
,
,
,
and
1
Division of Applied chemistry and Biochemistry, National Institute of Technology, Tomakomai College, Nishikioka 443, Tomakomai 059-1275, Japan
2
Department of Bioresources Engineering, National Institute of Technology, Okinawa College, Henoko 905, Nago 905-2192, Japan
*
Authors to whom correspondence should be addressed.
Gels2026, 12(1), 5;https://doi.org/10.3390/gels12010005 
(registering DOI)
This article belongs to the Special Issue Design and Optimization of Pharmaceutical Gels (2nd Edition)

Abstract

Carboxymethylcellulose (CMC) is a biocompatible and biodegradable polysaccharide suitable for biomedical applications. Herein, an epichlorohydrin (ECH)-crosslinked CMC hydrogel (CMCG) was developed as a carrier for sustained drug release. Ether-type crosslinking between the hydroxyl groups of CMC and ECH yielded a transparent, highly water-absorbent gel. Structural analyses employing Fourier-transform infrared and solid-state 13C nuclear magnetic resonance spectroscopies confirmed successful crosslinking, and the hydrogel exhibited pH-dependent swelling. Carboplatin (CBP), a platinum-based anticancer drug, was incorporated into CMCG to prepare CBP-CMCG. In phosphate-buffered saline (pH 7.4), approximately 70% of CBP was released within 12 h, followed by a plateau phase, indicating diffusion-controlled release. Cytocompatibility assays using WI-38 normal human fibroblasts demonstrated that CMCG was non-cytotoxic, whereas free CBP induced significant cell death. In colorectal cancer HT-29 cells, CBP-CMCG exhibited gradual cytotoxicity, resulting in >80% nonviable cells after 24 h, indicating a sustained antitumor effect compared with free CBP. These results demonstrate that the newly developed ECH-crosslinked CMC hydrogel is a safe and effective platform for controlled drug delivery, enabling sustained release and prolonged therapeutic activity of CBP.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.